# Cancer and CHC Funding | Nellie Supports

Source: https://www.nelliesupports.com/chc-guides/chc-funding-cancer

Canonical: https://www.nelliesupports.com/chc-guides/chc-funding-cancer

Written by: Ben Slater

Source review by: Kerry Slater

Source review recorded: 2026-07-20

# Cancer and NHS Continuing Healthcare funding

Cancer can lead to care needs from the illness, treatment or both. CHC eligibility depends on those needs. Fast Track is appropriate where an appropriate clinician identifies a rapidly deteriorating condition that may be entering a terminal phase; a cancer diagnosis alone does not decide the route.

Cancer can lead to care needs from the illness, treatment or both. CHC eligibility depends on those needs. Fast Track is appropriate where an appropriate clinician identifies a rapidly deteriorating condition that may be entering a terminal phase; a cancer diagnosis alone does not decide the route.

## Consider Fast Track first

Where the condition is deteriorating rapidly and may be entering a terminal phase, an appropriate clinician can complete a Fast Track Pathway Tool and funding should follow urgently, with no Checklist or Decision Support Tool required. Oncology and palliative care teams complete many of these. Where the trajectory is clear, this is by far the quicker route.

## When the standard route applies

If the Fast Track criteria are not met but needs may indicate a primary health need, ask about the standard CHC route. Living longer with advanced cancer or continuing active treatment does not itself exclude Fast Track. The appropriate clinician should consider the current trajectory and anticipated needs, without imposing a fixed remaining-life limit.

## Treatment effects

Treatment may cause needs such as fatigue, neuropathy, lymphoedema, nausea or infection risk. Record those actually present, how long they last and the care required across treatment cycles. Short-term or recovering needs may affect when CHC assessment is appropriate, but interim clinical and care support should still be addressed.

## Symptom control

Pain, nausea, breathlessness and agitation may require complex regimes, frequent as required medication and repeated adjustment. Where a syringe driver is in use, that requires trained management and monitoring. Difficult symptom control engages the medication domain, which can reach priority, and speaks to nature and complexity.

## Needs from advanced disease

Bone metastases bringing fracture risk and pain, brain metastases bringing cognitive change, seizures and behavioural change, spinal cord compression, malignant wounds requiring specialist dressing, and lymphoedema management. Each engages specific domains and each is frequently recorded only in clinical correspondence rather than in the assessment.

## Fluctuation across treatment cycles

A person may be reasonably independent early in a cycle and highly dependent later, which is a fluctuation pattern assessments regularly miss. State where in the cycle the assessment took place and describe the range across the whole cycle rather than the day of the meeting.

## Key takeaway

Ask about Fast Track first where the trajectory is deteriorating. Where it is not, use the standard route rather than waiting. Record treatment effects and cycle fluctuation, and carry the needs from advanced disease out of clinical letters and into the domains.

## Frequently asked questions

### Should we use Fast Track for cancer?

Where the condition is deteriorating rapidly and may be entering a terminal phase, yes, and oncology or palliative care teams complete many of these tools. Where the trajectory is not rapid, the standard route applies.

### What if we are told to wait for Fast Track?

Ask the treating clinician whether the Fast Track criteria apply now. If they do not, and ongoing needs may indicate CHC eligibility, ask for the standard route to be considered. A Checklist or DST must not delay action on a valid Fast Track tool.

### Do treatment side effects count?

Yes, describe the side effects actually present and their effect on care needs, including duration and variation across a treatment cycle. The assessment timing may need to distinguish short-term recovery from ongoing needs. Required support should still be arranged while that is considered.

### Does a syringe driver matter?

Include its care and monitoring requirements and the person’s symptom-control needs. A syringe driver alone does not determine the medication-domain level. The descriptor must fit the actual symptoms, response to treatment, monitoring and professional intervention required.

### How do we handle treatment cycle fluctuation?

State where in the cycle the assessment occurred and describe the range across the whole cycle, since assessments frequently capture the better part of it.

## A practical next step

Ask the oncology or palliative care team to explain current needs, likely changes and whether the Fast Track criteria apply. Provide a representative record across treatment cycles and the current symptom-control plan. Do not assume either ongoing treatment or a cancer diagnosis decides the funding route.

## Related NHS Continuing Healthcare pages

These pages explain related stages of the NHS Continuing Healthcare process in England. The service page describes optional paid support.

[NHS Continuing Healthcare Support](https://www.nelliesupports.com/services/continuing-healthcare)

[Fast Track CHC explained](https://www.nelliesupports.com/education-pages/fast-track-chc-explained)

[What rapidly deteriorating means](https://www.nelliesupports.com/chc-guides/rapidly-deteriorating-fast-track)

[The drug therapies and medication domain](https://www.nelliesupports.com/chc-guides/chc-domain-medication)

[Why a diagnosis alone does not decide CHC eligibility](https://www.nelliesupports.com/chc-guides/diagnosis-does-not-decide-chc)

## Sources and further reading

Department of Health and Social Care (2022) National Framework for NHS Continuing Healthcare and NHS-funded Nursing Care. Available at: [https://www.gov.uk/government/publications/national-framework-for-nhs-continuing-healthcare-and-nhs-funded-nursing-care](https://www.gov.uk/government/publications/national-framework-for-nhs-continuing-healthcare-and-nhs-funded-nursing-care)

Department of Health and Social Care (2022) NHS Continuing Healthcare Decision Support Tool.

National Institute for Health and Care Excellence. Clinical guidance. Available at: [https://www.nice.org.uk](https://www.nice.org.uk/)

R v North and East Devon Health Authority, ex parte Coughlan [2000] 2 WLR 622.

Written by Ben Slater, Registered Social Worker, Founder and Managing Director of Nellie Supports

Reviewed by Kerry Slater, Director of Operations

Last reviewed: 2026-07-20

## Author and Publication

Author: Ben Slater, Registered Social Worker, Founder and Managing Director of Nellie SupportsReviewed by: Kerry Slater, Director of OperationsLast reviewed: 20 July 2026

## Citation

1. Department of Health and Social Care (2022) National Framework for NHS Continuing Healthcare and NHS-funded Nursing Care. Available at: [https://www.gov.uk/government/publications/national-framework-for-nhs-continuing-healthcare-and-nhs-funded-nursing-care](https://www.gov.uk/government/publications/national-framework-for-nhs-continuing-healthcare-and-nhs-funded-nursing-care)2. Department of Health and Social Care (2022) NHS Continuing Healthcare Decision Support Tool.3. National Institute for Health and Care Excellence. Clinical guidance. Available at: [https://www.nice.org.uk](https://www.nice.org.uk/)4. R v North and East Devon Health Authority, ex parte Coughlan [2000] 2 WLR 622.

## Copyright

Copyright © 2026 Nellie Supports Ltd. All rights reserved.

This article is made available for general information, education and professional reference. It may be downloaded, printed and shared for non-commercial purposes, provided that it is reproduced in full, is not altered in any way, and is properly cited as the work of Nellie Supports Ltd. This material must not be edited, adapted, sold, republished, incorporated into commercial products, or used for commercial training, assessment, report-writing or advisory services without prior written permission from Nellie Supports Ltd.

This article does not constitute legal advice, clinical advice or a substitute for a decision-specific professional assessment. Where legislation, government guidance, court forms or external professional materials are referred to, those materials remain subject to their own copyright, licensing and re-use terms.

## Abstract

This guide explains how NHS Continuing Healthcare eligibility is assessed where a person has cancer. It covers when the Fast Track route applies, the position for people living with cancer over a longer period, treatment effects, symptom control, the needs arising from advanced disease, and the evidence that supports an accurate assessment.

## What’s on this page

- [Overview](https://www.nelliesupports.com/chc-guides/chc-funding-cancer)

- [Related Pages](https://www.nelliesupports.com/chc-guides/chc-funding-cancer)

## Related NHS Continuing Healthcare pages

### Fast Track CHC explained

### What rapidly deteriorating means

### The drug therapies and medication domain

### Why a diagnosis alone does not decide CHC eligibility

## Further help with the process

This guide covers NHS Continuing Healthcare in England. Ask the ICB's continuing healthcare team about the next stage and any local forms or deadlines. For an enquiry to Nellie Supports, call [0333 987 5118](tel:03339875118). You do not need to buy private support to request an NHS assessment or challenge a decision.

## Primary sources and official guidance

[Official NHS Continuing Healthcare Decision Support Tool](https://www.gov.uk/government/publications/nhs-continuing-healthcare-decision-support-tool)

## Related information

- [NHS Continuing Healthcare Support](https://www.nelliesupports.com/services/continuing-healthcare)

---

Nellie Supports Ltd · 0333 987 5118 · nellie@nelliesupports.com

Office 11 and 12, Unit 20, Springfield Business Park, Grantham, NG31 7FZ
